Navigation Links
Entry of Biogenerics and Decreasing Use of Amgen's Epogen and Johnson & Johnson's Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
Date:10/29/2007

Upheaval is Forecasted for the Markets of Five Chemotherapy Side Effect

Indications, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chemotherapy-induced anemia will decline by $2.8 billion over the next decade owing to the entry of several biogeneric products and decreasing use of erythropoiesis-stimulating proteins, including Amgen's Epogen and Johnson & Johnson's Procrit.

The new Pharmacor report entitled Managing the Side Effects of Chemotherapy finds that biogeneric erosion combined with emerging safety concerns and an increasingly restrictive reimbursement landscape for erythropoiesis-stimulating proteins will cause the chemotherapy-induced anemia market to decline from $4.5 billion in 2006 to $1.7 billion in 2016. The report also finds that the chemotherapy-induced neutropenia market will decrease $1 billion by 2016 because of the entry of biogeneric versions of Amgen's Neupogen in 2008 in Europe and in 2013 in the United States.

Sales for the most common side effects of chemotherapy-anemia, neutropenia, thrombocytopenia, chemotherapy-induced nausea and vomiting, and oral mucositis-totaled more than $8 billion in 2006 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. According to the report, the market is dominated by therapies that manage anemia and neutropenia effectively for most patients, but considerable opportunity remains for drugs that address thrombocytopenia and oral mucositis, indications characterized by a lack of effective therapies.

"There will be upheaval in the markets for all five of the indications we looked at," said Ramya Kollipara, Ph.D., analyst at Decision Resources. "The decline in drug-treatment rates and the introduction of biogenerics will substantially constrain the market for anemia therapies through 2016, causing the value of the market to fall by nearly a third. Biogeneric erosion will also have a significant impact on the market for neutropenia therapies, and the introduction of novel emerging therapies will have a dramatic impact on the market for anti-thrombocytopenia agents as well."

The chemotherapy-induced nausea and vomiting market will see patent expiries of multiple agents that are thoroughly ingrained in physician treatment algorithms. For oral mucositis, the only available agent, Amgen's Kepivance, is approved only for the prevention of oral mucositis in patients receiving stem cell transplants, but increasing treatment rates and the launch of the first therapy for solid tumor patients will transform the oral mucositis market over the next ten years.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sentry Insurance to add 30 IT jobs in Fox Valley
2. Fiserv plans single entry point for loan processing online
3. Johnson Controls deals for asset-tracking software
4. Johnson Controls adds renewable energy unit
5. Johnson Controls unit lands contract for plug-in hybrid battery
6. Johnson Controls to expand in Europe
7. Johnson Controls partners on car satellite linkup
8. Florida schools employ Johnson Controls technology to stop sex predators
9. Johnson Controls partnership wins new contract
10. Johnson Controls appoints Roell to head EOC
11. Johnson Controls reports record quarterly sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):